Markku H. Vaarala

5.3k total citations
53 papers, 1.5k citations indexed

About

Markku H. Vaarala is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Markku H. Vaarala has authored 53 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 17 papers in Molecular Biology and 15 papers in Surgery. Recurrent topics in Markku H. Vaarala's work include Prostate Cancer Treatment and Research (13 papers), Prostate Cancer Diagnosis and Treatment (9 papers) and Bladder and Urothelial Cancer Treatments (9 papers). Markku H. Vaarala is often cited by papers focused on Prostate Cancer Treatment and Research (13 papers), Prostate Cancer Diagnosis and Treatment (9 papers) and Bladder and Urothelial Cancer Treatments (9 papers). Markku H. Vaarala collaborates with scholars based in Finland, United States and China. Markku H. Vaarala's co-authors include Katja Porvari, Pirkko Vihko, Saila Kauppila, Pasi Hirvikoski, Atte P. Kyllönen, Marja‐Riitta Väisänen, Ari Ristimäki, O Lukkarinen, Sakari Kellokumpu and Pasi Ohtonen and has published in prestigious journals such as Oncogene, International Journal of Cancer and European Urology.

In The Last Decade

Markku H. Vaarala

51 papers receiving 1.4k citations

Peers

Countries citing papers authored by Markku H. Vaarala

Since Specialization

Citations

This map shows the geographic impact of Markku H. Vaarala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markku H. Vaarala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markku H. Vaarala more than expected).

Fields of papers citing papers by Markku H. Vaarala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markku H. Vaarala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markku H. Vaarala. The network helps show where Markku H. Vaarala may publish in the future.

Co-authorship network of co-authors of Markku H. Vaarala

This figure shows the co-authorship network connecting the top 25 collaborators of Markku H. Vaarala. A scholar is included among the top collaborators of Markku H. Vaarala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markku H. Vaarala. Markku H. Vaarala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dampened Regulatory Circuitry of TEAD1/ITGA1/ITGA2 Promotes TGFβ1 Signaling to Orchestrate Prostate Cancer Progression 2024 ·Advanced Science ·(unknown), Qin Zhang, (unknown), (unknown), (unknown), Kai Zhang, (unknown), (unknown), Ji‐Han Xia, Anne Ahtikoski, Markku H. Vaarala, Tomasz Wenta, Gong‐Hong Wei, Aki Manninen	8
2	Nationwide analysis of survival after radical cystectomy for bladder cancer in Finland 2023 ·Acta Oncologica ·(unknown), Antti Salminen, Heikki Seikkula, (unknown), Ileana Montoya Perez, (unknown), Jukka Sairanen, (unknown), Teemu J. Murtola, Markku H. Vaarala, (unknown), Timo K. Nykopp, Taina Isotalo, Timo Marttila, (unknown), (unknown), Christian Palmberg, Peter J. Boström	2
3	Disassembly of α6β4-mediated hemidesmosomal adhesions promotes tumorigenesis in PTEN-negative prostate cancer by targeting plectin to focal adhesions 2022 ·Oncogene ·Tomasz Wenta, (unknown), Qin Zhang, (unknown), (unknown), (unknown), Anne Ahtikoski, Markku H. Vaarala, Gong‐Hong Wei, Aki Manninen	19
4	Transition to Targeted Therapies Improved the Prognosis and Increased the Utilization of Medical Treatments among Patients with Synchronous Metastatic Renal Cell Cancer 2021 ·International Journal of Surgical Oncology ·(unknown), Hanna Ronkainen, Markku H. Vaarala	0
5	Multiparametric MRI prior to radical prostatectomy identifies intraductal and cribriform growth patterns in prostate cancer 2019 ·British Journal of Urology ·(unknown), Anne Ahtikoski, Mari Kuisma, Eija Pääkkö, Pasi Hirvikoski, Markku H. Vaarala	28
6	Symptoms and diagnostic delays in bladder cancer with high risk of recurrence: results from a prospective FinnBladder 9 trial 2019 ·World Journal of Urology ·(unknown), Otto Ettala, Ileana Montoya Perez, Riikka Järvinen, (unknown), Markku H. Vaarala, (unknown), Tapani Liukkonen, Timo Marttila, S. Aaltomaa, Eero Kaasinen, Peter J. Boström	7
7	Lesion size on prostate magnetic resonance imaging predicts adverse radical prostatectomy pathology 2018 ·Scandinavian Journal of Urology ·(unknown), Mari Kuisma, Eija Pääkkö, Pasi Hirvikoski, Markku H. Vaarala	15
8	External beam radiation for the treatment of castration-resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients 2017 ·Molecular and Clinical Oncology ·Teele Kuusk, (unknown), Markku H. Vaarala	1
9	Mass spectrometric identification of diagnostic markers for chronic prostatitis in seminal plasma by analysis of seminal plasma protein clinical samples 2017 ·Cellular and Molecular Biology ·Anne Rokka, Aare Mehik, (unknown), Markku H. Vaarala	2
10	Prostate cancer incidence in men with self-reported prostatitis after 15 years of follow-up 2016 ·Oncology Letters ·Markku H. Vaarala, Aare Mehik, Pasi Ohtonen, Per M. Hellström	4
11	DuraSeal® as a spacer to reduce rectal doses in low-dose rate brachytherapy for prostate cancer 2014 ·Radiotherapy and Oncology ·(unknown), (unknown), Markku H. Vaarala	12
12	Expression of Toll-like receptor-9 is associated with poor progression-free survival in prostate cancer 2013 ·Oncology Letters ·Marja‐Riitta Väisänen, Arja Jukkola‐Vuorinen, Katri Vuopala, Katri S. Selander, Markku H. Vaarala	39
13	Changing trends in symptomatology, diagnostics, stage and survival of prostate cancer in Northern Finland during a period of 20 years 2013 ·World Journal of Surgical Oncology ·(unknown), (unknown), Aare Mehik, (unknown), (unknown), Ilkka Paananen, Pekka Kunelius, Markku H. Vaarala, Pasi Ohtonen, Per M. Hellström	5
14	Identification of androgen-regulated genes in human prostate 2012 ·Molecular Medicine Reports ·Markku H. Vaarala, Pasi Hirvikoski, Saila Kauppila, Timo Paavonen	49
15	Evaluation of neuroendocrine markers in renal cell carcinoma 2010 ·Diagnostic Pathology ·Hanna Ronkainen, Ylermi Soini, Markku H. Vaarala, Saila Kauppila, Pasi Hirvikoski	27
16	HuR expression is a marker of poor prognosis in renal cell carcinoma 2010 ·Tumor Biology ·Hanna Ronkainen, Markku H. Vaarala, Pasi Hirvikoski, Ari Ristimäki	27
17	The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer 2008 ·International Journal of Cancer ·Markku H. Vaarala, Henna Mattila, Pasi Ohtonen, Teuvo L.J. Tammela, Timo Paavonen, Johanna Schleutker	35
18	The Androgen Receptor CAG Repeat Length Polymorphism Associates with Prostate Volume in Finnish Men with Benign Prostatic Hyperplasia 2007 ·DNA and Cell Biology ·(unknown), Eeva‐Riitta Savolainen, (unknown), Timo Paavonen, Markku H. Vaarala	3
19	Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues 2001 ·The Journal of Pathology ·Markku H. Vaarala, Katja Porvari, Sakari Kellokumpu, Atte P. Kyllönen, Pirkko Vihko	144
20	Prostatic expression of human 5α-reductase type 2 during finasteride therapy: a randomized, double-blind, placebo-controlled study 2000 ·World Journal of Urology ·Markku H. Vaarala, O Lukkarinen, Timo Marttila, Atte P. Kyllönen, Katja Porvari, Pirkko Vihko	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact